Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.
about
Current clinical application of serum biomarkers to detect ovarian cancerIn 2014, can we do better than CA125 in the early detection of ovarian cancer?The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomasProteomics of ovarian cancer: functional insights and clinical applicationsCancer cell-specific oligopeptides selected by an integrated microfluidic system from a phage display library for ovarian cancer diagnosis.Plasma levels of MMP-7 and TIMP-1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers.CA 125 and other tumor markers in uterine leiomyomas and their association with lesion characteristicsBiomarkers in uterine leiomyomaComparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer.Serum HE4 is more suitable as a biomarker than CA125 in Chinese women with benign gynecologic disordersM-CSF in a new biomarker panel with HE4 and CA 125 in the diagnostics of epithelial ovarian cancer patientsComparison of specific ovarian tumor markers by elecsys analyzer 2010Extremely elevated CA-125 in benign ovarian disease due to stretch of the peritoneumIdentifying post-menopausal women at elevated risk for epithelial ovarian cancerOvarian cyst fluid is a rich proteome resource for detection of new tumor biomarkers.Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomasAssessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic massThe use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer.The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors.Is CA72-4 a useful biomarker in differential diagnosis between ovarian endometrioma and epithelial ovarian cancer?Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125.HE4 Serum Levels in Patients with BRCA1 Gene Mutation Undergoing Prophylactic Surgery as well as in Other Benign and Malignant Gynecological Diseases.Biomarkers for early detection of ovarian cancer.Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.Physiopathological factors affecting the diagnostic value of serum HE4-test for gynecologic malignancies.Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma.Genomic markers of ovarian adenocarcinoma and its relevancy to the effectiveness of chemotherapy.Role of osteopontin in differential diagnosis of ovarian tumors.Serum endocan levels in endometrial and ovarian cancers.Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology.Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?Comparison of HE4 and CA125 levels in women with benign gynecologic disorders : Does age or menopausal status matter?Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients?Preoperative serum levels of cancer antigen 125 and carcinoembryonic antigen ratio can improve differentiation between mucinous ovarian carcinoma and other epithelial ovarian carcinomas.Does the Risk of Ovarian Malignancy Algorithm Provide Better Diagnostic Performance Than HE4 and CA125 in the Presurgical Differentiation of Adnexal Tumors in Polish Women?
P2860
Q26768709-9ADC7DE5-E764-4B22-9326-A6A5EE49BEEEQ26825152-E33DC067-32DE-4CAF-BC24-CCE7BCD47EE9Q26992102-3DA44250-67AE-4840-BC77-38A1DD402D90Q28082632-E21FE84E-F50B-4F5C-918D-E03B0EEEEB23Q30418500-A27E608D-7A8F-4284-8A66-887994C3D893Q32173966-E4E81CB8-8E7D-4541-A1F4-537E4FDD7DEFQ33756335-93E70577-29C2-431C-BD81-1FA3BB679602Q34406190-2FB8748A-48ED-4D77-8556-CE97A965A465Q34675023-C7B1AF96-7BAB-4D7B-909D-A77654E76F3BQ35207172-96729EF8-A7A1-468E-9AF7-4A1065781051Q35589339-8CA50DFD-3786-48C8-8932-56EF94B73DC1Q35601405-D6828D43-93C1-4286-A1A9-EE0A11E9E350Q35978597-1AB84825-7026-4456-8FAB-05286DB86EBAQ36331643-3683D7A4-02A2-42BB-A527-BE856A2B7EA1Q36556482-A1A0CD60-B282-4FB7-9DFA-E09E6AB7D221Q36565979-2014C4CC-A148-487E-9915-F242183DE816Q36904090-4A18978C-2F6D-48B2-A71A-508A5C18A97BQ36982622-25848CDF-8339-49C6-8D47-6DCF6747118BQ36996525-B78F0C4A-BB04-4777-B97B-BCFD391BF250Q37221882-8DC2443C-F7D2-4FFD-9BFD-B1E98213B881Q37406838-92AA4D80-7F31-464B-9AB3-7FB11892A672Q37611329-6E31414B-C6B1-42C4-ADF2-A269EF33DF9AQ38087982-0F0A01C0-E77C-4764-90E5-C14F018BC49BQ38819035-93CC624B-32B0-487A-8E46-3CEC415E5F5DQ38991579-88B82E24-8751-40B2-B0B2-DE3D52E29513Q41006936-F76F6D91-5529-44A1-9343-F77E3806ACA4Q41615733-58E071F0-2941-4A96-8115-ECF9B96C9F2DQ47960574-02E78F44-221A-443C-9EC6-94E437A09C38Q47982714-E511E576-206E-4F3C-ABB7-F00C4596DEB1Q48227450-36E9A932-E65E-4054-87B5-972D13337781Q50857141-2E04583D-2838-4C66-B953-1298A1BC94AEQ51382154-C0F463E1-A44B-4BED-BD5A-66C19231F758Q52627963-4C556ED1-5E0C-47E8-B06A-CF6A6F659861Q55250506-EB20A2CF-58FC-4E29-A3E1-2B846782D918Q55280402-601CF12D-CA64-43F6-8644-EC1B0A027738
P2860
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 December 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Serum HE4 levels are less freq ...... benign gynecologic disorders.
@en
Serum HE4 levels are less freq ...... benign gynecologic disorders.
@nl
type
label
Serum HE4 levels are less freq ...... benign gynecologic disorders.
@en
Serum HE4 levels are less freq ...... benign gynecologic disorders.
@nl
prefLabel
Serum HE4 levels are less freq ...... benign gynecologic disorders.
@en
Serum HE4 levels are less freq ...... benign gynecologic disorders.
@nl
P2093
P2860
P1476
Serum HE4 levels are less freq ...... benign gynecologic disorders.
@en
P2093
Geralyn Lambert-Messerlian
Karen H Lu
Margaret M Steinhoff
Michael Craig Miller
Richard G Moore
Steven J Skates
P2860
P304
P356
10.1016/J.AJOG.2011.12.029
P407
P577
2011-12-30T00:00:00Z